Partial Lipodystrophy,Polycystic Ovary Syndrome and Proteinuria: A Common Link to Insulin Resistance?

Walker M. Insulin resistance; a problem for clinicians and scientists. Diabet Med 2000; 17: 406–8

Black M. , Cunliffe W. Subcutaneous fat: lipodystrophy. In: Champion R. , Burton J. , Burns D. , Breathnach S. , eds. Textbook of Dermatology. Oxford: Blackwell Scientific, 1998; 2426–32

Peters J.M. , Barnes R. , Bennett L. , Gitomer W.M. , Bowcock A.M. , Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21–22. Nature Genet 1998; 18: 292–5

Wilson W.A. , Sissons J.G. , Morgan OS. Multiple autoimmune diseases with bilateral optic atrophy and lipodystrophy. Ann Intern Med 1978; 89: 72–3

Walport M.J. , Davies K.A. , Botto M. C3 nephritic factor and SLE: report of four cases and review of the literature. Q J Med 1994; 87: 609–15

Alarcon-Segovia D. , Ramos-Niembro F. Association of partial lipodystrophy and Sjogren's syndrome [letter]. Ann Intern Med 1976; 85: 474–5

Piscatelli R.L. , Vieweg W.V. , Havel RJ. Partial lipodystrophy. Metabolic studies in three patients. Ann Intern Med 1970; 73: 963–70

Legro RS. Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol 1998; 145: 103–10

Eisinger A.J. , Shortland J.R. , Moorhead PJ. Renal disease in partial lipodystrophy. Q J Med 1972; 41: 343–54

Levy Y. , George J. , Yona E. , Shoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res 1998; 18: 55–60

Mathieson P.W. , Wurzner R. , Oliveria D.B. , Lachmann P.J. , Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993; 177: 1827–31

Demetriou K. , Kallikas I. , Zouvani I. , Kyriacou K. , Pierides A. The pregnant patient with partial lipodystrophy developing acute renal failure—onset of de novo membranoproliferative glomerulonephritis. Nephrol Dial Transplant 1998; 13: 2121–4

Cameron JS. The enigma of focal segmental glomerulosclerosis. Kidney Int 1996; 57(suppl): S119–S131

Carr A. , Samaras K. , Chisholm D.J. , Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyper-lipidaemia, and insulin resistance. Lancet 1998; 351: 1881–3

Murata H. , Hruz P.W. , Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251–4

Dellow E. , Unwin R.J. , Miller R.F. , Williams I.A. , Griffiths MH. Protease inhibitor therapy for HIV infection: the effect on HIV-associated nephrotic syndrome. Nephrol Dial Transplant 1999; 14: 744–7

Flier JS. Pushing the envelope on lipodystrophy. Nature Genet 2000; 24: 103–4

Shackleton S. , Lloyd D.J. , Jackson S.N. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nature Genet 2000; 24: 153–6

Hegele R.A. , Anderson C.M. , Wang J. , Jones D.C. , Cao H. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res 2000; 10: 652–8